Date: 2016-10-19
Type of information: Milestone
Compound: bispecific antibodies
Company: Merus (The Netherlands) Ono Pharmaceutical (Japan)
Therapeutic area: Autoimmune diseases
Type agreement: R&D - research - licensing
Action mechanism: bispecific antibody
Disease:
Details: In April 2014, Merus and Ono Pharmaceutical executed a research and license agreement to jointly develop bispecific antibody therapies in autoimmune diseases.
Financial terms:
Latest news:
- • On October 19, 2016, Merus announced that the company received an undisclosed milestone payment from Ono Pharmaceutical, under the ongoing collaboration between the two companies. The milestone was triggered as a result of pre-clinical confirmatory studies using the selected lead bispecific antibody candidate that Ono intends to advance into clinical testing. Ono and Merus have also extended their collaboration by signing an additional agreement for CMC activities to be carried out by Merus.
- In April 2015, Merus received a milestone payment for achieving preclinical proof-of-concept with a lead bispecific antibody.
Is general: Yes
